MYCIT

Serial Number 79267601
Registration 6132512
700

Registration Progress

Application Filed
Jul 1, 2019
Under Examination
Approved for Publication
Jun 9, 2020
Published for Opposition
Jun 9, 2020
Registered
Aug 25, 2020

Attorney Assistance

Section 71 Declaration Due (Principal Register 66a) (Based on registration date 20200825)
Due: Aug 25, 2026 221 days

Trademark Image

MYCIT

Basic Information

Serial Number
79267601
Registration Number
6132512
Filing Date
July 1, 2019
Registration Date
August 25, 2020
Published for Opposition
June 9, 2020
Drawing Code
4

Status Summary

Current Status
Active
Status Code
700
Status Date
Aug 25, 2020
Registration
Registered
Classes
005 009 010 042
+1 more

Rights Holder

BioNTech SE

94
Address
An der Goldgrube 12
55131 Mainz
DE

Ownership History

BioNTech SE

Original Applicant
94
DE

BioNTech SE

Owner at Publication
94
DE

BioNTech SE

Original Registrant
94
DE

Legal Representation

Attorney
Catherine C. Miller

USPTO Deadlines

Next Deadline
221 days remaining
Section 71 Declaration Due (Principal Register 66a) (Based on registration date 20200825)
Due Date
August 25, 2026
Grace Period Ends
February 25, 2027
Additional deadlines exist. Contact your attorney for complete deadline information.

Application History

37 events
Date Code Type Description Documents
Aug 25, 2025 REM3 E COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED Loading...
Apr 15, 2022 NREP P NEW REPRESENTATIVE AT IB RECEIVED Loading...
Dec 19, 2020 FINO P FINAL DECISION TRANSACTION PROCESSED BY IB Loading...
Dec 2, 2020 FICS P FINAL DISPOSITION NOTICE SENT TO IB Loading...
Dec 1, 2020 FIMP P FINAL DISPOSITION PROCESSED Loading...
Nov 25, 2020 FICR P FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB Loading...
Aug 25, 2020 R.PR A REGISTERED-PRINCIPAL REGISTER Loading...
Jun 9, 2020 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
Jun 9, 2020 PUBO A PUBLISHED FOR OPPOSITION Loading...
Jun 5, 2020 GPNX P NOTIFICATION PROCESSED BY IB Loading...
May 20, 2020 OPNS P NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB Loading...
May 20, 2020 OP2R P NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB Loading...
May 20, 2020 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Loading...
May 1, 2020 CNSA O APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Apr 29, 2020 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
Apr 28, 2020 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
Apr 28, 2020 ERFR I TEAS REQUEST FOR RECONSIDERATION RECEIVED Loading...
Mar 15, 2020 GNFN O NOTIFICATION OF FINAL REFUSAL EMAILED Loading...
Mar 15, 2020 GNFR O FINAL REFUSAL E-MAILED Loading...
Mar 15, 2020 CNFR R FINAL REFUSAL WRITTEN Loading...
Feb 21, 2020 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
Feb 18, 2020 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
Feb 18, 2020 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED Loading...
Feb 18, 2020 TCCA I TEAS CHANGE OF CORRESPONDENCE RECEIVED Loading...
Feb 18, 2020 CHAN I APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED Loading...
Feb 18, 2020 ARAA I ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED Loading...
Feb 18, 2020 REAP I TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED Loading...
Feb 18, 2020 COAR I TEAS CHANGE OF OWNER ADDRESS RECEIVED Loading...
Oct 26, 2019 RFNT P REFUSAL PROCESSED BY IB Loading...
Oct 7, 2019 RFCS P NON-FINAL ACTION MAILED - REFUSAL SENT TO IB Loading...
Oct 7, 2019 RFRR P REFUSAL PROCESSED BY MPU Loading...
Sep 28, 2019 RFCR E NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW Loading...
Sep 28, 2019 MAFR O APPLICATION FILING RECEIPT MAILED Loading...
Sep 27, 2019 CNRT R NON-FINAL ACTION WRITTEN Loading...
Sep 24, 2019 DOCK D ASSIGNED TO EXAMINER Loading...
Sep 24, 2019 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
Sep 19, 2019 REPR M SN ASSIGNED FOR SECT 66A APPL FROM IB Loading...

Detailed Classifications

Class 005
Pharmaceutical products for the treatment of cancer, in particular based on nucleic acids and/or proteins; personalised patient-specific medicinal products, in particular based on nucleic acids and/or proteins, namely, pharmaceutical preparations for treatment of cancer diseases, autoimmune diseases, and infectious diseases
Class 009
Scientific apparatuses and instruments, namely, next generation sequencers for laboratory research use; software algorithms, namely, downloadable software programs for use in analyzing next generation sequencer data, in particular for the detection and collection of mutations in cancer patients
Class 010
High-throughput analytical instruments, in particular instruments for next-generation sequencing (NGS) for medical issues, as well as for gene expression profiling and for the detection of epigenetic changes, namely, high throughput genome and exome gene sequencers for medical use
Class 042
Medical research and development in the field of cancer immunotherapy, in particular research and development in the field of human and veterinary medical diagnostics and treatment by means of molecular-biological, genetic, biotechnological and/or bioinformatic methods, in particular by means of next-generation sequencing; Scientific laboratory services and scientific research services featuring diagnostics of tumour markers for personalised treatment
Class 044
Medical, veterinary-medical and pharmaceutical advisory services, in particular in the selection of suitable treatments for cancer diseases of all kinds; Medical services, namely, performance of analyses and treatments as part of personalised cancer immunotherapy; Medical services for the treatment of cancer, namely, provision of treatments based on nucleic acids and/or checkpoint inhibitors

Classification

International Classes
005 009 010 042 044